Key result
Novel biomarkers like galectin-3 and sST-2 emerge as potential predictors of anthracycline-induced cardiotoxicity.
Why the study?
Anthracyclines cause dose-dependent cardiotoxicity limiting their use in breast cancer, and classical laboratory tests complicate risk stratification with low specificity.
Answers are grounded in this paper and cite their sources.
Emerging biomarkers such as galectin-3, sST-2, and MPO may offer improved specificity over classical markers for the early detection of anthracycline-induced cardiotoxicity in breast cancer patients.
Anthracyclines are effectively used in many therapeutic regimens for breast cancer (BC). However, the dose-dependent cardiotoxic effect causes certain limitations on their use. Laboratory tests for risk prediction and early diagnosis of anthracycline-induced cardiotoxicity (ACIC) based on measuring the activity and concentration of topoisomerase 2β, the levels of troponins T and I (TnT и TnI), N-terminal fragment of brain natriuretic peptide progenitor, remain relevant, but complicate the risk stratification with low specificity. Recently, the number of works devoted to the study of new biomarkers ACIC has been growing: galectin-3, soluble ST-2 (sST-2), and myeloperoxidase (MPO). In this review we analyzed current understanding of the classical markers ACIC and the results of recent studies dedicated to new predictors.
No takes yet. Share an insight, caveat, or question.
Kit et al. (2020) conducted a review in Breast cancer with anthracycline-induced cardiotoxicity. Biomarkers (topoisomerase 2β, troponins, NT-proBNP, galectin-3, sST-2, MPO) was evaluated. Classical and novel biomarkers, including galectin-3, sST-2, and myeloperoxidase, are being investigated for the risk prediction and early diagnosis of anthracycline-induced cardiotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: